KRYS - NASDAQ
Krystal Biotech, Inc.
$301.82
+0.74%Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
At a Glance
Live Snapshotkrys
Cash and Cash Equivalents
Last Annual Value
496.30M
3-Year CAGR
45%
5-Year CAGR
13%
10-Year CAGR
74%
Krystal Biotech, Inc. Competitors Analysis of Cash and Cash Equivalents
| Company | Cash and Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Krystal Biotech, Inc. NASDAQ:KRYS | 496.30M | 11.5% | 7.8% | 74.3% | |
 Arrowhead Pharmaceuticals, Inc. NASDAQ:ARWR | 226.55M | 26.9% | 4.2% | 10.3% | |
 Metsera, Inc. NASDAQ:MTSR | 352.45M | 67.4% | N/A | N/A | |
 Teleflex Incorporated NYSE:TFX | 393.26M | 20.8% | -2.4% | -3.2% | |
 Alkermes plc NASDAQ:ALKS | 1.12B | 34.8% | 27.1% | 19.6% | |
 Arcellx, Inc. NASDAQ:ACLX | 80.26M | -41.2% | 21.1% | N/A | |
 TG Therapeutics, Inc. NASDAQ:TGTX | 79.15M | -5.2% | -23.3% | 12.2% | |
 Protagonist Therapeutics, Inc. NASDAQ:PTGX | 128.39M | -11.7% | 0.8% | 19.8% | |
 Vaxcyte, Inc. NASDAQ:PCVX | 173.96M | -24.1% | 20.3% | N/A | |
 PTC Therapeutics, Inc. NASDAQ:PTCT | 984.65M | 18.3% | 39.0% | 15.6% |
Krystal Biotech, Inc. Fair Value Envelope
Related Guides
Continue your KRYS research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.